Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

Phase 3

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive
• Interventions: Drug: cilomilast

• Registration Number: NCT00103922
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11
• Study First Submitted: 2005-02-17
• Study First Submitted QC: 2005-02-17
• Study First Posted: 2005-02-18
• Primary Completion: 2007-01
• Study Completion: 2007-01
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-26
• Last Update Posted: 2016-10-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 1	cilomilast	-

Primary Outcome Measures

Name	Time	Method
measure of lung function and quality of life in patients with COPD

Secondary Outcome Measures

Name	Time	Method
exacerbations in patients with COPD

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Milwaukee, Wisconsin, United States